Research and Markets: Phosphodiesterases: A Drug Target Family with Broad Therapeutic Impact

Dublin - Research and Markets (http://www.researchandmarkets.com/reports/c23020) has announced the addition of Phosphodiesterases: A Drug Target Family with Broad Therapeutic Impact to their offering

Phosphodiesterases (PDEs) are the enzyme superfamily of drug targets that underlie PDE inhibitor development. As such, PDEs are emerging as a promising class of drug targets. The most significant recent development for PDE inhibitors was the approval of the first selective PDE inhibitor, Viagra(R), in 1998. Two further high profile approvals of new PDE inhibitors, which also address erectile dysfunction, have taken place. As industry awaits approval of two PDE inhibitors for new disease indications, the 'Phosphodiesterases: A Drug Target Family with Broad Therapeutic Impact' report highlights the broad applicability of PDEs, providing the reader with useful background information about current pipeline and market developments.

The central focus of the 'Phosphodiesterases: A Drug Target Family with Broad Therapeutic Impact' report is an assessment of the therapeutic and market potential of phosphodiesterase inhibitors. A systematic review of PDEs is presented, including review of the 11 known phosphodiesterase families. Pharma pipelines and disease indications addressed by PDE inhibitors aid review of their therapeutic potential. A market assessment reviews the disease markets addressed by current PDE inhibitors e.g. asthma, COPD and erectile dysfunction markets.

This report will allow you to:

- Determine what is new in PDE inhibitor development by review of clinical developments in current pharmaceutical pipelines.
- Assess the therapeutic potential of PDE inhibitors by identification of the major disease indications addressed by approved PDE inhibitors and those in clinical development.
- Assess the market potential of PDE inhibitors from maps of the current market landscape, an evaluation of the success of approved PDE inhibitors, and consideration of future market projections relevant to PDE inhibitors.
- Get an up-to-date perspective on PDE inhibitor targets with a systematic review of each PDE family.
- Identify the key technological platforms currently utilized in PDE-targeted drug discovery.
- Look inside 20 companies involved in PDE-related drug discovery, including their product pipelines, financial standing, partnerships & alliances, and more.
- Obtain a current industry snapshot of PDE-related drug discovery from a short survey conducted in parallel with the writing of this report.
- Gain insight into current challenges in PDE-related drug discovery through in-depth interviews with five industry experts.

This report answers the following questions:

- Who is currently developing PDE inhibitors?
- What are the disease indications addressed by PDE inhibitors in advanced clinical development?
- How are PDE inhibitors addressing unmet medical needs?
- What are the competitive advantages of second-generation PDE inhibitors?
- Why is a PDE program attractive in pharmaceutical R&D?
- What are the relative merits of approved PDE inhibitors?
- Which PDE targets are considered to have the most therapeutic and commercial potential?
- Which areas of PDE inhibitor development have high priority research needs?
- What are the future prospects for PDE inhibitors?

Companies profiled:

- ALTANA Pharma AG
- Bayer HealthCare
- Celgene Corp.
- CrystalGenomics, Inc
- deCODE genetics
- elbion AG
- GlaxoSmithKline, plc
- Glenmark Pharmaceuticals Ltd
- ICOS Corp.
- Inflazyme Pharmaceuticals Ltd
- Memory Pharmaceuticals Corp.
- Neuro3d
- Nissan Chemicals Industries Ltd
- Otsuka America Pharmaceutical, Inc
- Pfizer, Inc
- Plexxikon, Inc
- Sequenom, Inc
- Schering-Plough Corp.
- Wyeth
- Vivus, Inc

For more information visit http://www.researchandmarkets.com/reports/c23020

Laura Wood
Senior Manager
Research and Markets
press@researchandmarkets.com
Fax: +353 1 4100 980